Pulsenmore (PLSM)
Builds prescription-connected home ultrasound systems for remote clinician review.
$2.46
vs last close+0.09 (+3.80%)
In millions of USD, except per-share figures · converted from ILS at the latest rate
| In millions | Q2 FY21Jun 2021 | Q4 FY21Dec 2021 | Q2 FY22Jun 2022 | Q4 FY22Dec 2022 | Q2 FY23Jun 2023 | Q4 FY23Dec 2023 | Q2 FY24Jun 2024 | Q4 FY24Dec 2024 | Q2 FY25Jun 2025 | Q4 FY25Dec 2025 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 13 | 2 |
| Cost of revenue | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 2 | 1 |
| Gross profit | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 11 | 1 |
| 3 | 5 | 7 | 10 | 10 | 9 | 7 | 8 | 7 | 13 | 8 | |
| Research & development | 2 | 2 | 3 | 6 | 6 | 5 | 3 | 3 | 3 | 5 | 3 |
| 1 | 3 | 3 | 4 | 4 | 5 | 4 | 5 | 5 | 5 | 5 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 |
| Operating income | −3 | −4 | −6 | −9 | −9 | −9 | −7 | −7 | −7 | −2 | −7 |
| 0 | −1 | 5 | 3 | 2 | −3 | 1 | 0 | −1 | −1 | −5 | |
| Interest income | 0 | 0 | 3 | 3 | 3 | 2 | 2 | 0 | 1 | 1 | 1 |
| Interest expense | 0 | 1 | 0 | 0 | 0 | 5 | 0 | 0 | 2 | 0 | 6 |
| Other non-operating income | 0 | 0 | −5 | −3 | −3 | −2 | −2 | 0 | −1 | 1 | 0 |
| Income before tax | −3 | −6 | −1 | −6 | −7 | −12 | −5 | −7 | −8 | −3 | −12 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| Net income from continuing operations | −3 | −6 | −1 | −6 | −7 | −12 | −5 | −7 | −8 | −3 | −12 |
| Net income | −3 | −6 | −1 | −6 | −7 | −12 | −5 | −7 | −8 | −3 | −12 |
| EPS, basic | −$0.50 | −$0.96 | −$0.18 | −$0.99 | −$1.18 | −$1.89 | −$0.83 | −$1.09 | −$1.19 | −$0.46 | −$1.87 |
| EPS, diluted | −$0.50 | −$0.96 | −$0.18 | −$0.99 | −$1.18 | −$1.89 | −$0.83 | −$1.09 | −$1.19 | −$0.46 | −$1.87 |
| Weighted average shares, basic | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 |
| Weighted average shares, diluted | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 |
| EBITDA | −2 | −4 | −1 | −6 | −7 | −6 | −5 | −6 | −6 | −3 | −7 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| EBIT | −3 | −4 | −1 | −6 | −7 | −7 | −5 | −7 | −6 | −3 | −7 |
